Medicine and Dentistry
Melanoma
100%
Colorectal Carcinoma
61%
Neoplasm
57%
Breast Cancer
42%
Sentinel Node
37%
Recurrent Disease
35%
Sentinel Lymph Node
35%
Diseases
32%
Metastatic Carcinoma
30%
Lymph Node
29%
Sentinel Lymph Node Biopsy
27%
Retroperitoneal Lymph Node Dissection
23%
Biopsy Technique
18%
Surgeon
15%
Iodine 125
15%
Carcinoembryonic Antigen
15%
Melanoma Skin Cancer
14%
Monoclonal Antibody CC49
13%
Technetium-99
13%
Malignant Neoplasm
13%
Quadrantectomy
12%
Tumor Infiltrating Lymphocyte
12%
Overall Survival
12%
Lymphoscintigraphy
12%
Sentinel-Node Mapping
11%
Sentinel Lymph Node Metastasis
11%
Monoclonal Antibody
11%
Hazard Ratio
10%
Lymph Node Metastasis
10%
Mitomycin
9%
Magnetic Resonance Imaging
8%
Single Photon Emission Computed Tomography-Computed Tomography
8%
Colon Carcinoma
8%
Recurrence Risk
7%
Scintigraphy
7%
Neck
7%
Lumpectomy
7%
Squamous Cell Carcinoma
7%
Liver Metastasis
6%
Venous Ulcer
6%
Radioisotope
6%
Mastectomy
6%
Surgical Exploration
6%
Recurrence Free Survival
6%
Disease Free Survival
6%
Metastatic Melanoma
6%
Long Term Survival
6%
Pelvis
5%
Decision Making
5%
Surgical Technique
5%
Keyphrases
Melanoma
72%
Sentinel Lymph Node
43%
Sentinel Lymph Node Biopsy
42%
Tumor
33%
Monoclonal Antibody
30%
CC49
26%
Melanoma-specific Survival
26%
Recurrent Colorectal Cancer
26%
Sentinel Lymph Node Mapping
25%
Detecting Probe
21%
Breast Cancer
20%
Colorectal Cancer
19%
Lymph Node
19%
Colorectal Carcinoma
16%
Melanoma Patients
16%
Confidence Interval
15%
Breast Reconstruction
14%
Breast Cancer Patients
13%
Metastatic Melanoma
13%
Surgeons
13%
125I
13%
International Society
12%
Tumor-infiltrating Lymphocytes
12%
Hazard Ratio
12%
Lymphoscintigraphy
12%
Radiolabeled Antibody
12%
Prognostic Value
12%
Overall Survival
12%
Metastasis
12%
Sentinel Lymph Node Metastasis
11%
Blue Dye
11%
Carcinoembryonic Antigen
10%
Disease-free Survival
10%
Tumor Site
10%
Completion Lymph Node Dissection
10%
Sentinel Node Metastasis
10%
Lymph Node Metastasis
10%
Lymph Node Status
9%
Handheld
9%
Malignant Melanoma
9%
Recurrence-free Survival
9%
Recurrence Rate
9%
Node-positive
8%
Intraperitoneal Hyperthermic Perfusion
8%
Thick Melanoma
8%
Carcinoembryonic Antigen Levels
8%
SPECT-CT
8%
Phase II Trial
8%
CT System
8%
Tilmanocept
8%